Real-World Impact of Once-Weekly Injectable Semaglutide (sema OW) vs. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Health Care Resource Utilization (HCRU) Outcomes in Type 2 Diabetes (T2D)-An Observational Study (PAUSE)

被引：0
|
作者：
Amamoo, James
Doshi, Riddhi P.
Noone, Joshua
Xie, Lin
Gamble, Cory L.
Guevarra, Mico
Divino, Victoria
Chen, Justin
King, Aaron A.
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1884-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1884-LB
引用
收藏
页数：2
相关论文
共 34 条
  • [1] Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)
    James Amamoo
    Riddhi Doshi
    Joshua Noone
    Lin Xie
    Cory Gamble
    Mico Guevarra
    Victoria Divino
    Justin Chen
    Aaron King
    Diabetes Therapy, 2025, 16 (5) : 1033 - 1048
  • [2] Real-World Impact of Once-Weekly Injectable Semaglutide on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes-An Observational Study (PAUSE)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Divino, Victoria
    Chen, Justin
    King, Aaron A.
    DIABETES, 2024, 73
  • [3] Real-World Impact of Once-Weekly Injectable Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE-OW Injectable Semaglutide)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Tan, Xi
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Chen, Justin
    King, Aaron A.
    DIABETES, 2023, 72
  • [4] Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience
    Tumminia, Andrea
    Graziano, Marco
    Vinciguerra, Federica
    Lomonaco, Andrea
    Frittita, Lucia
    PRIMARY CARE DIABETES, 2021, 15 (02) : 283 - 288
  • [5] Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) versus dipeptidyl peptidase 4 inhibitors (DPP-4i) in T2D patients across different HBA1c levels
    D'Andrea, Elvira
    Wexler, Deborah
    Paik, Julie
    Alt, Ethan
    Kim, Seoyoung
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 331 - 332
  • [6] Predictors of HbA1c and Weight Response to Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in the Association of British Clinical Diabetologist (ABCD) UK Nationwide Audit
    Crabtree, Thomas S. J.
    Gallagher, Alison
    Sivappriyan, Siva
    Dhatariya, Ketan
    Raghavan, Rajeev P.
    Bickerton, Alex
    Elliott, Jackie
    Cull, Melissa L.
    Rayman, Gerry
    Gallen, Ian W.
    Idris, Iskandar R.
    Ryder, Robert E.
    DIABETES, 2022, 71
  • [7] Impact of Once-Weekly Semaglutide on eGFR and Hemoglobin A1c (HbA1c) among Patients with Type 2 Diabetes and CKD: An Observational Study
    Amamoo, James J.
    Sheth, Sunny T.
    Brady, Brenna L.
    Tran, Anh Thu
    Xie Lin
    Noone, Josh
    Mehanna, Sherif
    Bakris, George L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [8] Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 mg Weekly Dose of Once-Weekly Semaglutide for Diabetes
    Gronroos, Noelle N.
    Swift, Caroline
    Frazer, Monica S.
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2024, 11 (02): : 118 - 124
  • [9] Comparative Efficacy of Ertugliflozin (ERTU) vs. Other Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): Model-Based Meta-analysis (MBMA) of HbA1c Lowering
    Fediuk, Daryl
    Mandema, Jaap
    Sweeney, Kevin
    Terra, Steven G.
    Sahasrabudhe, Vaishali
    DIABETES, 2019, 68
  • [10] Individualized Cost-Effectiveness Assessment of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) vs. Sulfonylureas as Add-On Therapy in People with Inadequately Controlled Type 2 Diabetes (T2D) Under Metformin Monotherapy
    Guan, Dawei
    Niu, Shu
    Fonseca, Vivian
    Shi, Lizheng
    Laiteerapong, Neda
    Guo, Jingchuan
    Shao, Hui
    DIABETES, 2022, 71
1234